Recetved:3 December 2022 Accepted:20 January2023D0L:10.1111/bph.18682BJHaemGUIDELINEManagement of patients with germline predisposition tohaematological malignancies considered for allogeneic blood andmarrow transplantation:Best practice consensus guidelines fromthe UK Clinical Genetics Group(UKCGG),CanGene-CanVar,NHS England Genomic Laboratory Hub (GLH)HaematologicalMalignancies Working Group and the British Society of Blood andMarrow Transplantation and cellular therapy(BSBMTCT)Andrew Clark'Sally Thomas2 Angela Hamblin3 Polly TalleyAustin Kulasekararajs Jacob Grinfeld Beverley Speight Katie SnapeTerri P.McVeigh John A.Snowden10Scottish BMT and Cellular Therapy Programme,Queen Elizabeth University Hospital,Glasgow,ScotlandDepartment of Haematology,Sheffield Teaching Hospitals NHS Foundation Trust,Royal Hallamshire Hospital,Sheffield,UKDepartment of Haematology.Oxford University Hospitals NHS Foundation TrustChurchill Hospital.Oxford.UKHaematological Malignancy Diag nostic Service(HMDS).St James's University Hospital.Leeds.UKDepartment of Haematological Medicine,King's College Hospital,Denmark Hill,Londonand King's College London,London,UKDepartment of Pediatric Haematologyand Oncology.Leeds Childrens Hospital,Leeds,UKEast Anglian Medical Genetics Service.Cambridge.UKSouth West Thames Regional Genetics Service,St George's University Hospitals NHS Foundation Trust,London,UKCancer Genetics Unit,Royal Marsden NHS FoundationTrust,London,UKDepartment of Haematology.Sheffiel BMT and Cellular Therapy Programme.Sheffield Teaching Hosptals NHS Foundation Trust,Sheffiek,UKCorrespondenceAndrew Clark,Scottish BMT and CellularSummaryTherapy Programme,Queen ElizabethGermline predisposition to haematological cancers is increasingly being recognisedUniversity Hospital,1345 Govan Road,Glasgow G51 4TF,UK.Widespread adoption of high-throughput and whole genome sequencing is iden-Email:andrew.clark@ggc.scot.nhs.uktifying large numbers of causative germline mutations.Constitutional pathogenicvariants in six genes (DEAD-box helicase 41 [DDX41],ETS variant transcriptionfactor 6 [ETV6],CCAAT enhancer binding protein alpha [CEBPA],RUNX familytranscription factor 1 [RUNX I],ankyrin repeat domain containing 26 [ANKRD26]and GATA binding protein 2 [GATA2])are particularly significant in increasing therisk of haematological cancers,with variants in some of these genes also associatedwith non-malignant syndromic features.Allogeneic blood and marrow transplanta-tion(BMT)is central to management in many haematological cancers.Identificationof germline variants may have implications for the patient and potential familydonors.Beyond selection of an appropriate haematopoietic stem cell donor thereTerri P.MeVeigh and John A.Snowden are joint last authors.This is anopen access article under the terms of the Creative Commons Attr ibution-NonCommercial License,which permits use,distribution and reproduction in anymedium,provided the original work is properlycited and is not used for co
